Connect with us

Health

Demand in Addiction Treatment Spikes During COVID-19 Pandemic

mm

Published

on

Since the beginning of the COVID-19 pandemic in early 2020, we have seen a dramatic rise in addiction and the subsequent need for treatment across America. According to a poll by the Kaiser Family Foundation, almost half of all Americans currently believe that the pandemic is harming their mental health.

This has led to a 1,000 percent increase in the number of calls received by a federal emergency hotline in April 2020 when compared to the same month last year. The hotline, run by the Substance Abuse and Mental Services Administration, saw 20,000 people text the number in April alone.

Talkspace, an online therapy company, has also reported a 65% spike in clients since the middle of February, around when the Coronavirus started making significant headway across America and Europe.

Co-founder and CEO of Talkspace, Oren Frank, told the Washington Post: “People are really afraid. What’s shocking to me is how little leaders are talking about this. There are no White House briefings about it. There is no plan.”

Similarly, Telehealth virtual visits increased by 50% in March alone, including addiction treatment services.

Frank also revealed that the rise in demand for services such as his own followed almost exactly the same rise as the virus itself across the United States.

Experts have analysed the patterns shown after economic downturns, terrorist attacks, and natural disasters and have subsequently predicted a continued spike in overdose deaths and substance abuse.

Meadows Mental Health Policy Institute hypothesized that an additional 4,800 people could lose their lives due to overdoses due to the current pandemic.

In the face of such a clear and alarming rise in mental health issues and a dependence on substances such as alcohol and drugs, the government advice is to continue treatment wherever possible.

Despite this, the United States federal substance abuse and mental health agency revealed in May that only 1 percent of the desired funding had been granted to them.

The Substance Abuse and Mental Health Services Administration issued the following statement: “For those with substance use disorders, inpatient/residential treatment has not been shown to be superior to intensive outpatient treatment. Therefore, in these extraordinary times of risk of viral infection, it is recommended that intensive outpatient treatment services be utilized whenever possible.”

What is even more worrying is that, like the vast majority of businesses, treatment facilities are also struggling in the current financial climate.

In May, 57% of surveyed organizations in North Carolina revealed that they had already been forced to close one of their programs due to financial constraints. 27% had laid off staff and 43% precited that they would have to close altogether by June.

As the issue of addiction continues to spiral out of control with sufferers confined to their own homes and denied access to face-to-face treatment, the demand on what few services remain seems to be unstable.

It remains to be seen whether the US government diverts further funds to ease the strain on addiction treatment in the following months as the COVID-19 pandemic reigns on.

A multi-lingual talent head, Jimmy is fluent in languages such as Spanish, Russian, Italian, and many more. He has a special curiosity for the events and stories revolving in and around US and caters an uncompromising form of journalistic standard for the audiences.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

BioLongevity Labs: How Two Biohackers Are Making Longevity Safe for the Mainstream

mm

Published

on

Humans have been looking for ways to extend their lifespan for hundreds of years. Medicine has made impressive strides, but for many, the effects of aging are still painfully real.

Through BioLongevity Labs, biohackers and entrepreneurs Jay Campbell and Josh Felber aim to introduce ordinary people to potentially life-changing compounds called peptides. Campbell and Felber come from very different backgrounds.

Campbell is a five-time international bestselling author and globally recognized leader in the health-optimization space. Felber is a serial entrepreneur who excels at scaling businesses.

For both men, BioLongevity Labs is more than just a business venture — it’s about helping everyday people discover something that just might prolong and improve their lives.

“Your body inevitably changes as the years pile on,” says Campbell. “Your energy drops, and wrinkles start showing up uninvited. Peptides can change everything.”

Many people have probably heard the term “peptide” in passing. Some may know they’re associated with longevity. Most people just don’t have a strong grasp of how they work.

A peptide is a short chain of amino acids, which are the building blocks of proteins. Essentially, peptides are like shorter, simpler proteins. That might sound unremarkable, but the real magic of peptides lies in how they work.

They function as signaling or “messenger” molecules telling the body to perform specific functions. Many peptides function similarly to hormones. A relevant example is GLP-1 (glucagon-like peptide-1) receptor agonists. This class of medications includes semaglutide and tirzepatide, two wildly popular weight-loss drugs.

“These peptides aren’t just another biohacking fad,” Campbell explains. “They enhance insulin secretion and suppress glucagon release to balance blood sugar levels and promote sustainable weight loss”. But what sets GLP-1 receptor agonists apart is their ability to regulate hunger.

Through the reduction of appetite and increased feelings of fullness, it is far easier for dieters to stick to a calorie deficit.” Although GLP-1 receptor agonists are widely prescribed, most peptides aren’t.

Campbell asserts, because many peptides have the potential to cure illnesses by treating the fundamental root cause, they go against America’s “sick care” model of healthcare. They potentially threaten drug companies and their bottom line.

“Peptides are simultaneously a dream come true for mankind and the worst possible nightmare for the pharmaceutical industry,” says Campbell. “It’s not a conspiracy theory. It’s pure economics and psychology in action. People will do whatever it takes to make as much money as possible in a free-market society, even if it means suppressing a superior solution.”

Patients probably aren’t going to be introduced to peptides through the healthcare system. Many discover them on their own. But for the many people who don’t have a solid understanding of how they work molecularly or even what dose to take, there is a risk. That’s precisely what BioLongevity Labs’ co-founders are attempting to address.

Jay Campbell has dedicated his life to educating people about therapeutic peptides and optimized hormones, and along with his partner Josh Felber, they’ve created a company offering filler-free, third-party tested peptides and bioregulators.

Campbell and Felber stress the fact that BioLongevity Labs isn’t meant to be a replacement for traditional medical care. Instead, its products bridge the gap between clinical and extra-clinical care. There’s no magic pill or single solution to solve the problem of aging.

But thanks to the development of specialized peptides, bioregulators, and small molecules, we’re closer than we’ve ever been before.

Continue Reading

Trending